Pharmaceuticals

Entry rationale

At the dated reference price, Lilly does not offer the entry discount our subjective scenario model requires for pricing, patent and execution risk. This is a price constraint, not an investment veto; a retreat below the model's buy threshold, with the operating thesis intact, would change the judgment.